Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Artrya Limited ( (AU:AYA) ) has issued an update.
Artrya Limited has released its Annual Report for 2025, highlighting significant statistics about coronary artery disease (CAD) and its impact on healthcare. The report underscores the urgency of addressing heart disease, with projections indicating that U.S. healthcare costs related to heart disease could surpass $1 trillion by 2035. The report emphasizes the critical nature of early detection and intervention, as a significant portion of the population experiences sudden death as the first sign of heart disease.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Average Trading Volume: 676,761
Technical Sentiment Signal: Buy
Current Market Cap: A$414.7M
See more insights into AYA stock on TipRanks’ Stock Analysis page.